| 1 |
Histamine H2R Signalling |
↓ H2R-mediated proliferative signalling (context-dependent) |
↓ H2R signalling in gastric parietal and immune cells |
R |
H2-receptor antagonism |
Established pharmacological mechanism; antitumour consequences depend on histamine sensitivity and tumour microenvironment. |
| 2 |
E-selectin / Sialyl Lewis Adhesion |
↓ Endothelial adhesion and metastatic attachment |
↓ Endothelial surface E-selectin |
R/G |
Antimetastatic adhesion inhibition |
Particularly relevant to colorectal tumours expressing sLeX or sLeA. Effect appears partly H2R-independent and is supported by experimental metastasis models. |
| 3 |
NK Cells / Cytotoxic T-cell Immunity |
↑ Immune-mediated tumour-cell elimination (context-dependent) |
↑ NK and effector T-cell function (context-dependent) |
G |
Restoration of antitumour surveillance |
Reversal of histamine-associated immune suppression; human perioperative studies support immune preservation but not all specific cellular mechanisms. |
| 4 |
Treg / Immunosuppressive Microenvironment |
↓ Immune escape (indirect) |
↓ Histamine-associated regulatory suppression (context-dependent) |
G |
Immunomodulation |
Effects on FoxP3-associated Treg activity and suppressive immune populations are model-dependent; evidence is predominantly experimental. |
| 5 |
IL-12 / IL-10 / Th1–Th2 Balance |
↑ Cell-mediated antitumour response (indirect) |
↑ IL-12; ↓ IL-10; ↑ Th1-associated activity (context-dependent) |
G |
Proimmune cytokine modulation |
Reverses selected histamine-mediated cytokine responses. Not a demonstrated universal systemic cytokine effect. |
| 6 |
Perioperative Immune Suppression |
↓ Opportunity for immune escape (indirect) |
↑ Preservation of lymphocyte proliferation and cell-mediated immunity |
G |
Postoperative immune preservation |
Small randomized colorectal surgery studies reported attenuation of postoperative immune suppression. |
| 7 |
Proliferation / Apoptosis |
↓ Proliferation; ↑ apoptosis (model-dependent) |
↔ Variable |
G |
Direct tumour-growth inhibition |
Reported in selected cancer cell lines. Some effects may be H2R-independent; pharmacologically achievable exposure remains uncertain. |
| 8 |
Angiogenesis / VEGF-associated Signalling |
↓ Angiogenic support (model-dependent) |
↓ Proangiogenic signalling (model-dependent) |
G |
Potential antiangiogenic activity |
Secondary preclinical mechanism; insufficient evidence to establish direct VEGF inhibition as a principal human effect. |
| 9 |
Androgen Receptor Signalling |
↓ Androgen signalling (weak; context-dependent) |
↓ Androgen receptor activity |
G |
Weak antiandrogenic action |
Pharmacologically relevant to gynecomastia and other endocrine adverse effects; clinical antitumour leverage is unproven. |
| 10 |
Drug Metabolism / CYP Inhibition |
↔ Indirect effects through altered drug exposure |
↓ Hepatic metabolism of multiple medications |
R/G |
Pharmacokinetic interactions |
Clinically significant interaction potential, including with anticoagulants, anticonvulsants, beta-blockers and some oncology drugs. Not equivalent to proven chemosensitization. |
| 11 |
Clinical Translation Constraint |
↔ Response varies by tumour type and adhesion-marker expression |
↑ Drug exposure in renal impairment; possible CNS and endocrine adverse effects |
R/G |
Limits clinical application |
Historical small RCTs, uncertain modern treatment benefit, limited mechanistic PK validation and substantial drug-interaction potential. No established oncology dosing protocol. |